STOCK TITAN

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, has announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. The company will host a conference call at 4:30 p.m. (Eastern Time) on the same day to discuss the results.

Investors can access the live call through the Investor Relations section of Insulet's website or by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, using the passcode 5904836. The call will be archived for future replay on the company's website.

Insulet is known for its Omnipod Insulin Management System, which provides a unique alternative to traditional insulin delivery methods. The company's flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor and can be controlled by a compatible personal smartphone in the U.S.

Insulet (NASDAQ: PODD), leader globale nella tecnologia delle pompe per insulina senza tubi, ha annunciato piani per rilasciare i suoi risultati finanziari del terzo trimestre del 2024 il 7 novembre 2024 dopo la chiusura dei mercati finanziari. L'azienda ospiterà una conferenza telefonica alle 16:30 (Ora orientale) dello stesso giorno per discutere i risultati.

Gli investitori possono accedere alla chiamata in diretta attraverso la sezione Relazioni con gli Investitori del sito web di Insulet o componendo il numero (888) 770-7129 per i chiamanti nazionali o (929) 203-2109 per i chiamanti internazionali, utilizzando il codice di accesso 5904836. La chiamata sarà archiviata per una riproduzione futura sul sito web dell'azienda.

Insulet è conosciuta per il suo Sistema di Gestione dell'Insulina Omnipod, che offre un’alternativa unica ai metodi tradizionali di somministrazione dell'insulina. Il prodotto di punta dell'azienda, il Sistema di Somministrazione Automatica dell'Insulina Omnipod 5, si integra con un monitoraggio continuo della glicemia e può essere controllato tramite uno smartphone personale compatibile negli Stati Uniti.

Insulet (NASDAQ: PODD), líder mundial en tecnología de bombas de insulina sin tubos, ha anunciado planes para publicar sus resultados financieros del tercer trimestre de 2024 el 7 de noviembre de 2024 después del cierre de los mercados financieros. La compañía llevará a cabo una conferencia telefónica a las 4:30 p.m. (Hora del Este) el mismo día para discutir los resultados.

Los inversores pueden acceder a la llamada en vivo a través de la sección de Relaciones con Inversores en el sitio web de Insulet o llamando al (888) 770-7129 para los llamantes nacionales o al (929) 203-2109 para los llamantes internacionales, utilizando el código de acceso 5904836. La llamada será archivada para futura reproducción en el sitio web de la empresa.

Insulet es conocida por su Sistema de Gestión de Insulina Omnipod, que proporciona una alternativa única a los métodos tradicionales de entrega de insulina. El producto estrella de la compañía, el Sistema de Entrega Automática de Insulina Omnipod 5, se integra con un monitor continuo de glucosa y puede ser controlado por un teléfono inteligente personal compatible en los EE. UU.

Insulet (NASDAQ: PODD)는 튜브 없이 인슐린을 주입하는 펌프 기술의 글로벌 리더로서 2024년 3분기 재무 결과를 2024년 11월 7일 마감 후 발표할 계획이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 (동부 표준시)에 결과를 논의하기 위한 전화 회의를 개최할 예정입니다.

투자자는 Insulet의 웹사이트 투자자 관계 섹션을 통해 생중계 전화에 접속하거나 국내 발신자는 (888) 770-7129, 국제 발신자는 (929) 203-2109로 전화하여 비밀번호 5904836을 사용하여 접속할 수 있습니다. 이 전화 회의는 회사 웹사이트에서 향후 재생을 위해 아카이브됩니다.

Insulet는 전통적인 인슐린 전달 방법에 대한 독특한 대안을 제공하는 Omnipod 인슐린 관리 시스템으로 잘 알려져 있습니다. 회사의 대표 제품인 Omnipod 5 자동 인슐린 전달 시스템은 지속적인 혈당 모니터와 통합되며, 미국에서는 호환 가능한 개인 스마트폰으로 제어할 수 있습니다.

Insulet (NASDAQ: PODD), leader mondial de la technologie des pompes à insuline sans tube, a annoncé ses projets de publier ses résultats financiers pour le troisième trimestre 2024 le 7 novembre 2024 après la clôture des marchés financiers. La société organisera une conférence téléphonique à 16h30 (heure de l'Est) le même jour pour discuter des résultats.

Les investisseurs peuvent accéder à l'appel en direct via la section Relations Investisseurs du site Web d'Insulet ou en composant le (888) 770-7129 pour les appels nationaux ou le (929) 203-2109 pour les appels internationaux, en utilisant le code d'accès 5904836. L'appel sera archivé pour une future rediffusion sur le site Web de l'entreprise.

Insulet est connue pour son Système de Gestion de l'Insuline Omnipod, qui offre une alternative unique aux méthodes traditionnelles de délivrance de l'insuline. Le produit phare de la société, le Système de Délivrance Automatique d'Insuline Omnipod 5, s'intègre avec un moniteur de glucose continu et peut être contrôlé par un smartphone personnel compatible aux États-Unis.

Insulet (NASDAQ: PODD), der globale Marktführer in der Technologie von tubuslosen Insulinpumpen, hat Pläne angekündigt, seine Finanzergebnisse für das dritte Quartal 2024 am 7. November 2024 nach dem Handelsende zu veröffentlichen. Das Unternehmen wird am selben Tag um 16:30 Uhr (Eastern Time) eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.

Investoren können die Live-Konferenz über den Bereich Investor Relations auf der Website von Insulet oder unter der Telefonnummer (888) 770-7129 für nationale Anrufer oder (929) 203-2109 für internationale Anrufer, unter Verwendung des Zugangscodes 5904836 erreichen. Die Konferenz wird für zukünftige Wiedergaben auf der Unternehmenswebsite archiviert.

Insulet ist bekannt für sein Omnipod Insulin Management System, das eine einzigartige Alternative zu traditionellen Insulinabgabemethoden bietet. Das Flaggschiffprodukt des Unternehmens, das Omnipod 5 automatisierte Insulinabgabesystem, lässt sich mit einem kontinuierlichen Glukosemonitor integrieren und kann in den USA von einem kompatiblen persönlichen Smartphone gesteuert werden.

Positive
  • None.
Negative
  • None.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved.

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

When will Insulet (PODD) release its Q3 2024 financial results?

Insulet (NASDAQ: PODD) will release its financial results for the third quarter of 2024 on November 7, 2024, after the close of the financial markets.

How can investors access Insulet's (PODD) Q3 2024 earnings call?

Investors can access Insulet's Q3 2024 earnings call on November 7, 2024, at 4:30 p.m. (Eastern Time) through the Investor Relations section of the company's website or by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, using the passcode 5904836.

What is Insulet's (PODD) main product?

Insulet's main product is the Omnipod Insulin Management System, with its flagship innovation being the Omnipod 5 Automated Insulin Delivery System, which integrates with a continuous glucose monitor and can be controlled by a compatible personal smartphone in the U.S.

What is unique about Insulet's (PODD) Omnipod insulin delivery system?

Insulet's Omnipod system is unique because it provides a tubeless, disposable Pod that delivers up to three days of non-stop insulin without the need to see or handle a needle, offering an alternative to traditional insulin delivery methods.

Insulet Corporation

NASDAQ:PODD

PODD Rankings

PODD Latest News

PODD Stock Data

16.23B
70.12M
0.34%
101.67%
3.95%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ACTON